The market is incredibly short sighted and can't value these companies properly.
Similar has happened to NEU. Reported a NPAT of 157m, 205m pretax for 2023. That's a 16 PE. Market punished that growth might only be 70% for their first approved product (via partner) for 2024, completely ignoring the fact the pipeline has a 10x TAM. Simplified the situation but it shows the average ASX investor has no idea how to value high quality biotech or medical stocks since we don't have many of them.
But somehow GYG's valuation is totally fine?
TLX is a buy and hold.
The market is incredibly short sighted and can't value these...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.44 |
Change
-0.320(1.54%) |
Mkt cap ! $6.840B | |||
| Open | High | Low | Value | Volume |
| $20.79 | $21.00 | $20.22 | $19.41M | 945.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $20.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.46 | 45 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |